CDT Equity (CDT) Share-based Compensation (2023 - 2026)
CDT Equity's (CDT) quarterly Share-based Compensation came in at $1.3 million in Q2 2026, down 18.75% on a YoY basis from $1.6 million in Q2 2025, and down 7.14% quarter-over-quarter from $1.4 million in Q1 2026.
Analysis
CDT Equity (CDT) Share-based Compensation (2023 - 2026) Analysis & Trends
CDT Equity (CDT) has reported Share-based Compensation for 4 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 18.75% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (down 18.75% YoY), and the FY2025 full-year result was $2.8 million, up 16.67% from the prior year.
- Share-based Compensation eased to $1.3 million in Q2 2026 per CDT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $72.4 million in Q3 2023 and bottomed at -$769000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $6.5 million across 4 years, with a median of $1.3 million in 2026.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 783.91% in 2025, then surged 498.29% in 2026.
- Over 4 years, Share-based Compensation stood at $393000.0 in 2023, then plunged by 122.14% to -$87000.0 in 2024, then tumbled by 783.91% to -$769000.0 in 2025, then surged by 269.05% to $1.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.3 million, $1.4 million, and -$769000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.92 Bn | 621.16 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 448.34 Bn | 441.78 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 357.85 Bn | 350.70 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 267.35 Bn | 259.66 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.52 Bn | 144.82 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | 277.20 Mn |
| 8 | Incyte | 24.69 Bn | 20.16 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | 19.00 Mn |
| 10 | CDT Equity | 183,138.46 | 183,138.46 | - | 1.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | -769,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | -87,000.00 |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 431,000.00 |
| Dec 31, 2023 | 393,000.00 |
| Sep 30, 2023 | 72.42 Mn |
| Mar 31, 2023 | 400,000.00 |